Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
Unified View of Claim Simplifies Workflow
Empowering SSDI and SSI Beneficiaries: Ticket to Work Program
View our informative video featuring Alyssa Tease, Ticket To Work Specialist, for an overview of the Ticket to Work program.
Thinking Beyond the Hospital: A Comprehensive Guide to Hospital Discharge Planning for Workers’ Compensation
Pain Management: Pharmacologic Alternatives to Opioids
In this webinar, we will learn about the pain pathway and the different types of pain as well as review the efficacy and adverse event profile of opioids. We’ll also learn pharmacologic alternatives to opioids and their recommended use, associated risks, and guideline-supported place in the treatment of work-related pain conditions, and gain a deeper understanding of the available interventions that will help injured workers recover function and manage pain.
Therapists at Forefront of Connecting Patients’ Physical, Mental wellness
The number of injured workers self-reporting anxiety and depression jumped “significantly” between 2019 and 2020 and had not yet returned to pre-pandemic rates in 2022.
Therapists at forefront of connecting patients’ physical, mental wellness
The number of injured workers self-reporting anxiety and depression jumped “significantly” between 2019 and 2020 and had not yet returned to pre-pandemic rates in 2022.